IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS (MRSA)
This study has been completed.
Sponsor:
University of Kentucky
Collaborator:
Pfizer
Information provided by:
University of Kentucky
ClinicalTrials.gov Identifier:
NCT00754273
First received: September 16, 2008
Last updated: March 22, 2011
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the prevalence of MRSA isolates with marginal susceptibility to vancomycin or heteroresistance.
| Condition | Intervention |
|---|---|
| Methicillin-resistant Staphylococcal Aureus Pneumonia | Other: etest susceptability testing |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Prospective Evaluation Of Protected Alveolar Lavage (PAL) Staphylococcus Aurues Resistance Patterns |
Resource links provided by NLM:
Further study details as provided by University of Kentucky:
Primary Outcome Measures:
- Determine the prevalence of PAL hetero-VISA within MRSA isolates using vancomycin E-tests and contrast this with E-tests for teicoplanin, linezolid and tigecycline. [ Time Frame: 1 time ]
Secondary Outcome Measures:
- Determine the sensitivity and specificity of automated susceptibility testing for PAL MRSA for vancomycin and alternative agents teicoplanin, linezolid and tigecycline by comparing automated sensitivity testing to E-test results. [ Time Frame: 1 time ]
| Estimated Enrollment: | 1250 |
| Study Start Date: | September 2008 |
| Study Completion Date: | July 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
PAL samples collected for pneumonia evaluation
|
Other: etest susceptability testing
E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
One hundred consecutive isolates of MRSA will be analyzed.
Criteria
Inclusion Criteria:
- Isolates of MRSA from PAL samples
Exclusion Criteria:
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00754273
Please refer to this study by its ClinicalTrials.gov identifier: NCT00754273
Locations
| United States, Kentucky | |
| University of Kentucky Medical Center | |
| Lexington, Kentucky, United States, 40536 | |
Sponsors and Collaborators
University of Kentucky
Pfizer
Investigators
| Principal Investigator: | Andrew C. Bernard, M.D. | University of Kentucky |
More Information
| Responsible Party: | Andrew Bernard, M.D., University of Kentucky Medical Center |
| ClinicalTrials.gov Identifier: | NCT00754273 History of Changes |
| Other Study ID Numbers: |
07-0775-P6H |
| Study First Received: | September 16, 2008 |
| Last Updated: | March 22, 2011 |
Additional relevant MeSH terms:
|
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on June 28, 2017